Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA) drives innovation in spatial biology through advanced tissue analysis platforms that transform clinical research and diagnostics. This news hub provides investors and researchers with essential updates on the company developments shaping precision medicine.
Access real-time press releases covering AKYA's scientific advancements, financial performance, and strategic partnerships. Our curated collection includes earnings reports, product launch details, and collaborative research initiatives within the life sciences sector.
Key updates feature progress in multiplex imaging technologies, biomarker discovery milestones, and regulatory developments impacting spatial biology applications. Track AKYA's contributions to oncology research, immunology studies, and next-generation diagnostic tools through verified corporate communications.
Bookmark this page for streamlined access to AKYA's official announcements, maintaining informed perspectives on their market position and technological leadership. Combine this resource with Stock Titan's financial analysis tools for comprehensive investment research.
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced its upcoming inclusion in the Russell 3000® Index, effective June 28, 2021. This membership positions Akoya for potential visibility and investment opportunities within the broader market, as it guarantees automatic inclusion in either the Russell 1000® or Russell 2000® Index. The company highlights this milestone following the successful IPO in April that raised $153.3 million, reinforcing its commitment to enhancing shareholder value and advancing its spatial biology platform.
Akoya Biosciences announces a partnership with AstraZeneca to enhance drug development using Akoya's Phenoptics™ platform, focusing on multiplex immunofluorescence (mIF) workflows and spatial biomarkers. This collaboration aims to improve understanding of cancer's immune biology, aiding in the identification of predictive biomarkers crucial for effective immunotherapy. The agreement seeks to streamline clinical trials and boost precision medicine, potentially increasing trial success rates. Akoya's ABS team will showcase its work at the ASCO Virtual Meeting from June 4-8, 2021.
Akoya Biosciences has launched Advanced Biopharma Solutions (ABS), a premium service designed to enhance drug development and clinical trials through spatial biomarker guidance. The ABS initiative aims to improve the accuracy of predictive biomarkers, ultimately reducing clinical trial failure rates, particularly in immunotherapy. Utilizing Akoya's Phenoptics™ mIF platform, this program supports biopharmaceutical companies with custom assay development and image analysis. The launch is significant in the context of advancing precision medicine and addressing challenges in identifying effective cancer treatments.
Akoya Biosciences (AKYA) reported Q1 2021 total revenue of $12.2 million, achieving the upper limit of its forecast. This reflects a growth from $11.0 million in Q1 2020. The company sold 37 instruments, including 20 CODEX, marking a significant sales increase. Gross profit rose to $7.4 million with a margin of approximately 61%. Akoya raised $151.3 million in an IPO and anticipates full-year revenue of at least $52.0 million, with Q2 growth expected at 45% over last year.
Akoya Biosciences (NASDAQ: AKYA) announced a co-marketing agreement with ZEISS for the CODEX® spatial phenotyping solution. This partnership aims to enhance the integration of Akoya's high-parameter CODEX system with the ZEISS Axio Observer microscope platform. The collaboration supports an affordable, open-access strategy aimed at advancing biological research across disciplines such as cancer and immunology. The partnership promises improved user experience and faster acquisition speeds, emphasizing Akoya's commitment to accessible ultra-high multiplex imaging.
Akoya Biosciences (Nasdaq: AKYA) will release its first quarter 2021 financial results after market close on May 18, 2021. Management will discuss these results during a conference call scheduled for 5:00 p.m. ET. Investors can participate by calling (833) 562-0146 domestically or (661) 567-1226 internationally, using Conference ID: 7824008. A live and archived webcast will also be available on the Akoya website.
Akoya is known for its spatial biology solutions, including CODEX® and Phenoptics™ platforms, which allow researchers to explore cell interactions in health and disease.
Akoya Biosciences (Nasdaq: AKYA) has launched its Imaging Innovators Network (I²), inviting researchers to apply innovative uses for the CODEX® system. This initiative aims to push the frontiers of spatial biology through open collaboration and cutting-edge applications. Initially, 10 researchers will be selected to leverage the CODEX system's capabilities, which can analyze over 40 biomarkers in tissue, enhancing disease research. Applications are open until July 9, 2021.
On May 3, 2021, Akoya Biosciences (Nasdaq: AKYA) completed its initial public offering (IPO) by issuing 7,567,000 shares at $20 per share, raising approximately $151 million. This offering included the underwriters' option to purchase an additional 987,000 shares. Akoya specializes in single-cell imaging solutions, utilizing its CODEX® and Phenoptics™ platforms to enhance research in disease progression and treatment response. DLA Piper facilitated this transaction, leveraging its expertise in capital markets and life sciences.
Akoya Biosciences, Inc. (Nasdaq: AKYA) successfully closed its initial public offering (IPO) of 7,567,000 shares at $20.00 per share, raising approximately $151.3 million in gross proceeds. The offering included the full exercise of underwriters' option to purchase an additional 987,000 shares. Trading began on April 16, 2021, on The Nasdaq Global Select Market under the symbol "AKYA." J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity acted as joint book-running managers. The registration statement for the offering was approved by the SEC on April 15, 2021.
Akoya Biosciences has announced the pricing of its initial public offering (IPO) of 6,580,000 shares at $20.00 each, raising approximately $131.6 million before expenses. The offering includes a 30-day option for underwriters to purchase up to 987,000 additional shares. Trading on the Nasdaq under the ticker symbol 'AKYA' is expected to commence on April 16, 2021, with closure anticipated by April 20, 2021, pending usual conditions. J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity are the joint book-running managers for this offering.
